Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever

Blood (2022) 140 (Supplement 1): 6494–6495.

https://doi.org/10.1182/blood-2022-165795

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Asciminib for CML: same target, new arrow

Charles A. Schiffer

Blood (2021) 138 (21): 2009–2010.

https://doi.org/10.1182/blood.2021013257

Published: 2021

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

Evaluating Factors Influencing Receipt of Stem Cell Transplant and Time to Transplant at a Diverse Metropolitan Transplant Center: Do Racial Disparities Persist?

Harsh Shah, DO, Seongho Kim, PhD, Scott Klimecki, Joseph P. Uberti, MD, PhD, Charles A. Schiffer, MD, Erlene K. Seymour, MD

Blood (2018) 132 (Supplement 1): 323.

https://doi.org/10.1182/blood-2018-99-110486

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

RUNX1 associated Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) in Children: A Novel New Phenotype with Juvenile and Chronic Myelomonocytic Leukemia (JMML/CMML) Characteristics

Katherine Regling, DO, Shruti Bagla, PhD, Ahmar Urooj Zaidi, MD BSc, Erin Wakeling, PhD, Michael C. Chicka, PhD, Leigh Flores, MD, Manisha Gadgeel, MBBS, MS, Steven Buck, MS, Meera B. Chitlur, MD, Charles A. Schiffer, MD, Yaddanapudi Ravindranath, MBBS

Blood (2018) 132 (Supplement 1): 5504.

https://doi.org/10.1182/blood-2018-99-116925

Published: 2018

Journal Articles

Real-World Testing and Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in the United States during the Modern Era: A SEER Patterns of Care Analysis

Erlene K. Seymour, MDBS, Julie J. Ruterbusch, M.P.H., Jennifer L. Beebe-Dimmer, PhD, M.P.H., Charles A. Schiffer, MD

Blood (2017) 130 (Supplement 1): 3384.

https://doi.org/10.1182/blood.V130.Suppl_1.3384.3384

Published: 2017

Journal Articles

Xpert ® BCR-ABL Ultra, a High Sensitivity Assay, Demonstrates a Limit of Detection Reaching MR4.5 and below

Christophe Ferrand, PhD, Marina Deschamps, PhD, Alba Levitas, Christina Lockwood, PhD, Jacqueline E. Payton, MDPhD, Geoffrey L. Uy, MD, Charles A. Schiffer, MD, Gerald Feldman, MD, Aaron Bossler, MD PhD, Julie Woolworth, PhD, Alice S. Mims, MD MSCR, Krupa Shridhar, Natalie Wu, PhD, Sandy Huang, Huilin Wei, MD PhD, Chris Lykke, PhD, Michael P. Bates, MD, Wendy Wong, Gwo-Jen Day, PhD

Blood (2017) 130 (Supplement 1): 1610.

https://doi.org/10.1182/blood.V130.Suppl_1.1610.1610

Published: 2017

Journal Articles

Results from the U.S. Life after Stopping TKIs (LAST) Study

Blood (2017) 130 (Supplement 1): 2903.

https://doi.org/10.1182/blood.V130.Suppl_1.2903.2903

Published: 2017

Journal Articles

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F List, MD, Zhuoxin Sun, PhD, Amit Verma, MD, John M. Bennett, MD, Kathy L McGraw, PhD, Lisa Ann Nardelli, BS, Jaroslaw P Maciejewski, MD PhD FACP, Jessica K Altman, MD, Puneet Cheema, MD, David F. Claxton, MD, Rami S. Komrokji, MD, Selina Luger, MD, Ryan Mattison, MD, Tim Wassenaar, MD, Andrew Artz, MD, Charles A Schiffer, MD, Martin S. Tallman, MD

Blood (2016) 128 (22): 223.

https://doi.org/10.1182/blood.V128.22.223.223

Published: 2016

Journal Articles

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Richard A. Larson, Rena Conti, PhD, William V. Padula, PhD, Jane F. Apperley, Michele Baccarani, MD, Ekkehard Eigendorff, MD, Francois Guilhot, MD, Joelle Guilhot, PhD, Francois-Xavier Mahon, MD PhD, Giovanni Martinelli, MD, Jiri Mayer, Prof., MD PhD, Martin C. Mueller, Dietger Niederwieser, MD, Susanne Saussele, MD, Charles A. Schiffer, MD, Richard T. Silver, MD, Bengt Simonsson, MD PhD, Rudiger Hehlmann, MD

Blood (2014) 124 (21): 738.

https://doi.org/10.1182/blood.V124.21.738.738

Published: 2014

Journal Articles

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Neil P. Shah, MD PhD, Philippe Rousselot, MD PhD, Charles A. Schiffer, MD, Delphine Rea, MD PhD, Jorge E. Cortes, MD, Jorge Milone, MD, Hesham Mohamed, MD, Diane Healey, MS, Hagop Kantarjian, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD

Blood (2014) 124 (21): 520.

https://doi.org/10.1182/blood.V124.21.520.520

Published: 2014

Journal Articles

Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy

Lakshminarayanan Nandagopal, MD, Muthu Veeraputhiran, Tania Jain, MBBS, Ayman Soubani, MD, Charles A. Schiffer, MD

Blood (2014) 124 (21): 4293.

https://doi.org/10.1182/blood.V124.21.4293.4293

Published: 2014

NARROW

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Asciminib for CML: same target, new arrow

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Evaluating Factors Influencing Receipt of Stem Cell Transplant and Time to Transplant at a Diverse Metropolitan Transplant Center: Do Racial Disparities Persist?

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

RUNX1 associated Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) in Children: A Novel New Phenotype with Juvenile and Chronic Myelomonocytic Leukemia (JMML/CMML) Characteristics

Real-World Testing and Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in the United States during the Modern Era: A SEER Patterns of Care Analysis

Xpert ® BCR-ABL Ultra, a High Sensitivity Assay, Demonstrates a Limit of Detection Reaching MR4.5 and below

Results from the U.S. Life after Stopping TKIs (LAST) Study

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only